Low skeletal muscle mass predicts melanoma-specific survival in melanoma patients treated with adjuvant immune checkpoint blockade
Journal of Cancer Research and Clinical Oncology · 2024
DOI: 10.1007/s00432-024-05812-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cancer Research and Clinical Oncology, 2024. Verfasst von Miriam Mengoni und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University Hospital Magdeburg, Leipziger Straße 44, 39120, Magdeburg, Germany. miriam.mengoni@med.ovgu.de. Hauptthemen laut MEDLINE: Melanoma, Immune Checkpoint Inhibitors, Muscle, Skeletal. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Else Kröner-Fresenius-Stiftung, Arbeitsgemeinschaft Dermatologische Forschung, Universitätsklinikum Magdeburg.
Abstract (Originalsprache)
Purpose
Adjuvant immunotherapy with immune checkpoint blockade(ICB) has greatly reduced the risk of recurrence and metastatic spread in early and advanced melanoma. However, not all patients benefit from adjuvant treatment: many patients show disease recurrence despite therapy, while those without recurrence harbor the risk for potentially irreversible adverse events. Biomarkers to select patients benefitting most from adjuvant therapy are currently lacking. As body composition assessment using CT images has shown promising results as a prognostic biomarker in stage IV melanoma, we aim to study the applicability of body composition parameters also in adjuvant melanoma treatment.
Methods
We analyze body composition features via CT scans in a retrospective cohort of 109 patients with resected stage IIB-IV melanoma receiving an adjuvant first-line treatment with ICB in our department. In this analysis, we focus on the impact of body composition, especially the presence of low skeletal muscle mass (LSMM), on patients’ survival and occurrence of adverse events (AEs).
Results
In uni- and multivariate analyses, we identify an association between CT-measured LSMM and melanoma-specific survival in patients treated with adjuvant ICB. Furthermore, LSMM is associated with a lower risk for therapy-related AEs, especially hypothyroidism, fatigue, and xerostomia. Conventional serological biomarkers e.g. S100 and LDH and measures of adipose tissue compartments did not show a correlation with survival or the occurrence of AEs.
Conclusions
LSMM constitutes a novel biomarker for melanoma-specific survival in patients treated with adjuvant ICB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, University Hospital Magdeburg, Leipziger Straße 44, 39120, Magdeburg, Germany. miriam.mengoni@med.ovgu.de.
- Department of Dermatology, University Hospital Magdeburg, Leipziger Straße 44, 39120, Magdeburg, Germany.
- Department for Radiology and Nuclear Medicine, University Hospital Magdeburg, Magdeburg, Germany.
- Department of Radiology, Neuroradiology and Nuclear Medicine, Johannes Wesling University Hospital, Ruhr University Bochum, Bochum, Germany.
Förderung
- Else Kröner-Fresenius-Stiftung
- Arbeitsgemeinschaft Dermatologische Forschung
- Universitätsklinikum Magdeburg
Zitieren
APA
Mengoni, M., Braun, A. D., Hinnerichs, M. S., Aghayev, A., Tüting, T., & Surov, A. (2024). Low skeletal muscle mass predicts melanoma-specific survival in melanoma patients treated with adjuvant immune checkpoint blockade. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-024-05812-4
Vancouver
Mengoni M, Braun AD, Hinnerichs MS, Aghayev A, Tüting T, Surov A. Low skeletal muscle mass predicts melanoma-specific survival in melanoma patients treated with adjuvant immune checkpoint blockade. Journal of Cancer Research and Clinical Oncology. 2024. doi:10.1007/s00432-024-05812-4
BibTeX
@article{Mengoni2024,
author = {Mengoni, Miriam and Braun, Andreas Dominik and Hinnerichs, Mattes Simon and Aghayev, Anar and Tüting, Thomas and Surov, Alexey},
title = {Low skeletal muscle mass predicts melanoma-specific survival in melanoma patients treated with adjuvant immune checkpoint blockade},
journal = {Journal of Cancer Research and Clinical Oncology},
year = {2024},
doi = {10.1007/s00432-024-05812-4}
}
EUVIMED